Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 18/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 17/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 13/20 | 0.55 |
| ▸ | HTR2B | P41595 | 4/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HTR5A | P47898 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358516 | 0.90 | ADORA3 (0.54) | ADORA3ADORA1ADORA2AHTR2BSLC6A2 | |
| SCHEMBL31350170 | 0.85 | HRH2 (0.43) | ADORA3ADORA1ADORA2AHTR2BHRH2 | |
| SCHEMBL31350206 | 0.84 | HRH2 (0.57) | ADORA3ADORA1ADORA2AHTR2BHRH2 | |
| SCHEMBL31350157 | 0.83 | HRH2 (0.56) | ADORA3ADORA1ADORA2AHTR2BHRH2 | |
| SCHEMBL31350143 | 0.79 | ADORA3 (0.38) | ADORA3ADORA1ADORA2AHTR2BHRH2 | |
| SCHEMBL31668923 | 0.79 | ADORA3 (0.64) | ADORA3ADORA1ADORA2AHTR2BSLC6A2 | |
| SCHEMBL31350227 | 0.78 | HTR2B (0.51) | ADORA3ADORA1ADORA2AHTR2BHRH2 | |
| SCHEMBL31350082 | 0.77 | ADORA1 (0.52) | ADORA3ADORA1ADORA2AHTR2BHRH2 | |
| SCHEMBL31350142 | 0.76 | HTR2B (0.53) | ADORA3ADORA1ADORA2AHTR2BHRH2 | |
| SCHEMBL31350180 | 0.76 | HTR2B (0.53) | ADORA3ADORA1ADORA2AHTR2BHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378248-B2 | A1 adenosine receptor agonists and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-08-05 | — | — | US | disclosed |
| US-20220024926-A1 | A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378248-B2 | A1 adenosine receptor agonists and methods of use thereof | ADORA1, ADORA2A, ADORA2B | ADORA3 4/4885ADORA1 1/4885ADORA2A 2/4885 |
| US-20220024926-A1 | A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF | ADORA1, ADORA2A, ADORA2B | ADORA3 4/4885ADORA1 1/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.